Aberdeen Group
NTLA icon

Aberdeen Group’s Intellia Therapeutics NTLA Stock Holding History

Aberdeen Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-243,044
Closed -$5.44M – 951
2024
Q2 		$5.44M Buy
243,044
+88,775
+58% +$2.11M 0.01% 606
2024
Q1 		$4.24M Hold
154,269
– – 0.01% 698
2023
Q4 		$4.7M Buy
+154,269
New +$4.43M 0.01% 677

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aberdeen Group's NTLA Position: Q3 2024 in Review

Aberdeen Group sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 243,044 shares — an estimated $5.44M sold.

Aberdeen Group first reported a position in NTLA in Q4 2023 and held it in 3 quarters. The position peaked at $5.44M in Q2 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Aberdeen Group reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 243,044 Intellia Therapeutics shares in Q3 2024, an estimated $5.44M.
  • Aberdeen Group first reported a position in Intellia Therapeutics in Q4 2023 and held it in 3 quarters.
  • Aberdeen Group's Intellia Therapeutics position peaked at $5.44M in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.